# Targeting-Recruitment Self-Assembly (TRA) Strategy

Literature Seminar 2022/12/24 Lin Yuanqi

# Contents

# 1. Introduction

2. In Situ Self-Assembly of Bispecific Peptide for Cancer Immunotherapy (Wang, M. D.; Lv, G. T.; An, H. W.; Zhang, N. Y.; Wang, H. Angew. Chem., Int. Ed. 2022, *61*, e202113649.)

# **Self-Assembling Peptide**

Peptide self-assembly is a process in which peptides spontaneously form ordered aggregates.



1) Lee, S.; Trinh, T. H.; Yoo, M.; Shin, J.; Lee, H.; Kim, J.; Ryou, C. Int. J. Mol. Sci. 2019, 20, 5850.

# **Self-Assembled Structures and Affected Factors**

nanostrctures		factors	
nanofibers		рН	hydrogen bonds, salt bridges, 
nanotubes		temperature	temperature- responsive
nanotapes		light	infrared (IR)- responsive
nanoparticles			
hydrogels			

1) Lee, S.; Trinh, T. H.; Yoo, M.; Shin, J.; Lee, H.; Kim, J.; Ryou, C. Int. J. Mol. Sci. 2019, 20, 5850.

# **Application in Cancer Treatment**

# targeting

LyP-1 (CGNKRTRGC) recognizes lymphatic metastatic tumors and exerts cytotoxic activity. LyP-1-conjugated PEG–PLGA nanoparticles (LyP-1-NPs) showed increased cellular uptake, thus showed good targeting efficiency to cancer cells.

# drug delivery

Nanomaterials as drug delivery carriers have many advantages including high efficiency for drug loading, a low ratio for drug loss, and high stability to avoid body clearance.



- 1) Lee, S.; Trinh, T. H.; Yoo, M.; Shin, J.; Lee, H.; Kim, J.; Ryou, C. Int. J. Mol. Sci. 2019, 20, 5850.
- 2) Fan, T.; Yu, X.; Shen, B.; Sun, L. J. Nanomater. 2017, 2017.

# Contents

**1. Introduction** 

2. In Situ Self-Assembly of Bispecific Peptide for Cancer Immunotherapy (Wang, M. D.; Lv, G. T.; An, H. W.; Zhang, N. Y.; Wang, H. Angew. Chem., Int. Ed. 2022, *61*, e202113649.)



# **Professor Hao Wang**

1996-2000	B.S. in Chemistry @Nankai University (Prof. Yu
	Liu)
2000-2005	Ph.D. in Chemistry @Nankai University (Prof. Yu
	Liu)
2006-2007	Alexander von Humboldt (AvH) Fellow
	@University of Würzburg (Prof. Frank Würthner)

- 2007-2010 Postdoctoral Fellow in Molecular and Medical Pharmacology @University of California (Prof. Hsian Rong Tseng)
- 2010-2011 Associate Professor in Molecular and Medical Pharmacology @University of California (Prof. Hsian Rong Tseng)

2011- Professor @National Center for Nanoscience and Technology of China

development of "in vivo self-assembly" technology in physiological/pathological conditions

nanomaterial

study of bio-effect and further regulation of biological behavior

exploration of self-assembled biomaterials for bioimaging, drug delivery, immunotherapy, etc

# **An Assembly Peptide: G7**

# self-assembly motif

# **G7: GNNQQNY**



- derived from yeast protein Sup35
- reported to form aggregate
- self-assemble into β-sheet nanofibers at high concentrations



Nelson, R.; Sawaya, M. R.; Balbirnie, M.; Madsen, A. Ø.; Riekel, C.; Grothe, R.; Eisenberg, D. *Nature*. **2005**, 435, 773.

# **RGD** Motif

RGD (receptor: integrin  $\alpha_V \beta_3$ )



Integrin  $\alpha_V \beta_3$  -targeting peptides with an exposed arginine-glycine-aspartate (RGD) sequence play a crucial role in targeted anticancer drug delivery.



Xiong, J. P.; Stehle, T.; Zhang, R.; Joachimiak, A.; Frech, M.; Goodman, S. L.; Arnaout, M. A. *Science* **2002**, *296*, 151.

# **Assembly Sequence: G7-RGD**



**G7: GNNQQNY** 

# G7-RGD (GNNQQNYRGD) bind the tumor-overexpressed protein receptor integrin $\alpha_V \beta_3$ on the cell membrane

# Targeting-Recruitment Self-Assembly (TRA) Strategy



The TRA strategy anchors self-assembling peptides to proteins, stabilizing peptide structures and triggering reduction in the activation energy of assembly. The immobilized peptides recruit surrounding monomers to drive the self-assembly process, which further mediates receptor oligomerization.

# **Assembly Concentration (CAC) in Solution**



**G7-RGD** + integrin  $\alpha_V \beta_3$ 







# **Model Experiment In Solution**



# Thermodynamics Investigation Using Surface Plasmon Resonance Imaging (SPRi)

 $K_{\rm D}$ : dissociation constant  $\Delta G$ :Gibbs free binding energy





$$\begin{split} \Delta G_{T} &: \text{ the binding energy G7-RGD targeting integrin } \alpha_{V}\beta_{3} \\ \Delta G_{S} &: \text{ the energy of G7-RGD self-assembly} \\ \Delta G_{TRA} &: \text{ the binding energy of targeted recruitment self-} \\ & \text{assembly} \\ \Delta G_{TRA} &= \Delta G_{T} + \Delta G_{RA} \end{split}$$

SPR readouts manifested that the targeting motif RGD upraised binding affinity and further induced self-assembly of TRA peptide to form aggregates with higher stability.

funnel-shaped potential energy landscape

# **Secondary Structure Study By CD Analysis**



# **TRA Design in Biological System**



kinetic fluorescence curve



**TEM** images



# **Self-Assembly on MCF-7 Membranes**

# confocal images

# 1 min

30 min





# SEM images



# 3D images





confirmation of self-assembly of G7-RGD self-assembly on the MCF-7 membrane

# **Probe Design**

G7-RGD rapidly self-assembled binding to integrin  $\alpha_V \beta_3$ 



self-assembly of G7-RGD on the membrane was a consequence of recruitment of surrounding free G7-RGD monomers



NBD-G7-RGD: NBD-X-GNNQQNY-RGD

emitting green fluorescence



# **Self-Assembled NBD-G7-RGD (1)**





NBD-G7-RGD initially self-assembled on the cell membrane to form aggregates, and then Cy-G7 monomers were recruited as building blocks.

foldamer-like



# **Self-Assembled NBD-G7-RGD (2)**

# adding G7-RGD prior to NBD-G7



adding G7 prior to NBD-G7



G7-RGD acted as the pre-assembly unit to target MCF-7 cells, followed by self-assembly and recruitment of the fluorescent building block NBD-G7.

# **Receptor Oligomerization**

physical drag force

G7-based self-assembly

receptor oligomerization

# confocal microscopy + flow cytometry



# after transfected using plasmid of integrin $\beta_3$ -EGFP







G7-RGD assembly caused oligomerization propensity of integrin  $\alpha_V \beta_3$ .

# **T-cell Activation**

CD3: a highly effective T cell membrane marker

TCR-CD3 complex recognizes the antigen that binds to the major histocompatibility complex (pMHC) to initiate antigen-specific T cell activation.



The T cell activation needs two signals:

The first one is the engagement of the antigen specific T Cell Receptor (TCR) with the antigen.

The second one is needed to activate helper CD4+ and cytotoxic CD8+ T cells.

During the process, CD28 which provides co-stimulatory signals and secreted interleukin-2 (IL-2) are necessary.

# **Assembly Sequences: G7-antiCD3**



**AKMGEGGWGANDY** (receptor: CD3)

self-assembly motif



**G7: GNNQQNY** 

# **Oligomerization of CD3**

# targeting motif to CD3

# G7-antiCD3: AKMGEGGWGANDY-GNNQQNY

(G7-antiCD3 containing 2 % NBD-G7-antiCD3)



# confocal images



The CD3-EGFP receptor was subjected to aggregation mediated by G7-antiCD3.

# **TRA Design**



# **Assembly Sequence: AntiCD3-G7-RGD**

targeting motif



**AKMGEGGWGANDY** (receptor: CD3)

# self-assembly motif

targeting motif



# **G7: GNNQQNY**



RGD (receptor: integrin  $\alpha_V \beta_3$ )

# **Aggregation of Self-Assembling Peptide on T Cells**



Time (h)

# **Tumor Cytolysis Mediated by TRA**



The IFN-γ protein is interferon produced by CD4 and CD8 T lymphocytes or activated NK cells.



T cells were activated by the antiCD3-G7-RGD.



# **Conclusion and Perspectives**



A specific and highly efficient in situ self-assembly strategy, TRA was developed.

A bispecific conjugate of antiCD3-G7-RGD was designed to not only promote oligomerization of CD3 receptors and activate T cells in vitro, but improve T cell-mediated tumor cytolysis.

